Investment banking firm Àrgentil Capital Partners has made an undisclosed amount of equity investment in Nigerian healthcare company Sygen Pharmaceuticals Limited through investment vehicle Consumer Growth Partners along with other undisclosed investors.

Incorporated in 2019, Sygen Pharmaceuticals Limited has produced and distributed pharmaceutical products for more than half a century in Nigeria. Prior to this, Sygen acquired operating assets of Nigerian German Chemicals in 2019. Àrgentil invests in small and medium size enterprises through Àrgentil Principal Investment Portfolio II whose key focus areas include Nigeria.